Snoval Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 11-12-2024
- Paid Up Capital ₹ 0.40 M
as on 11-12-2024
- Company Age 41 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 18.75 Cr
as on 11-12-2024
- Revenue %
(FY 2022)
- Profit -3.98%
(FY 2022)
- Ebitda -35.04%
(FY 2022)
- Net Worth 6.10%
(FY 2022)
- Total Assets 5.23%
(FY 2022)
About Snoval Pharmaceuticals
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.40 M.
The company currently has active open charges totaling ₹18.75 Cr.
Pallavi Lakdawala, Kirtikumar Lakdawala, Rakesh Lakdawala, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239MH1983PTC029344
- Company No.
029344
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Feb 1983
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Snoval Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pallavi Lakdawala  | Director | 01-Jan-1999 | Current |
| Kirtikumar Lakdawala | Director | 18-Jul-1995 | Current |
| Rakesh Lakdawala | Director | 01-Jan-1999 | Current |
| Jignesh Lakdawala | Director | 01-Jan-1999 | Current |
Financial Performance of Snoval Pharmaceuticals.
Snoval Pharmaceuticals Pvt Ltd, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 3.98% decrease in profit. The company's net worth moved up by a moderate rise of 6.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Snoval Pharmaceuticals?
In 2022, Snoval Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Tulips Medicaments Pvt LtdActive 41 years 10 monthsPallavi Lakdawala and Kirtikumar Lakdawala are mutual person
- Ecokrin Hygiene Private LimitedActive 23 years 1 month
Pallavi Lakdawala, Kirtikumar Lakdawala and 2 more are mutual person
- Skyline Holdings Pvt LtdActive 40 years 1 day
Pallavi Lakdawala, Kirtikumar Lakdawala and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 19 Jan 2022 | ₹6.00 Cr | Open |
Union Bank Of India Creation Date: 28 Jul 2004 | ₹12.75 Cr | Open |
How Many Employees Work at Snoval Pharmaceuticals?
Unlock and access historical data on people associated with Snoval Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Snoval Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Snoval Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
